Unfortunately, no data are available about the beneficial effects of a pharmacological modulation of ENT2 in other murine models of colitis, not allowing a comprehensive evaluation of its efficacy in intestinal inflammation supported by other immune paradigms. This evidence concerns the gene SLC29A2 and colitis.